STOCK TITAN

[Form 4] PROCEPT BioRobotics Corporation Insider Trading Activity

Filing Impact
(Low)
Filing Sentiment
(Positive)
Form Type
4
Rhea-AI Filing Summary

The filing shows that Antal Rohit Desai, a director of PROCEPT BioRobotics (PRCT), exercised stock options and acquired 26,749 shares on 08/14/2025 at a cash exercise price of $1.33 per share. After the transaction he beneficially owns 35,152 shares in total, including 14,363 shares held indirectly by The 2:22 DNA Trust. The option exercised was fully vested and exercisable, and the exercise was executed for cash. The Form 4 was signed by an attorney-in-fact on behalf of Mr. Desai on 08/15/2025.

La comunicazione indica che Antal Rohit Desai, direttore di PROCEPT BioRobotics (PRCT), ha esercitato opzioni su azioni acquisendo 26.749 azioni il 14/08/2025 a un prezzo di esercizio in contanti di $1.33 per azione. Dopo la transazione detiene beneficiariamente in totale 35.152 azioni, comprese 14.363 azioni detenute indirettamente da The 2:22 DNA Trust. L'opzione esercitata era completamente maturata ed esercitabile, e l'esercizio è avvenuto in contanti. Il Modulo 4 è stato firmato da un mandatario per procura in nome del Sig. Desai il 15/08/2025.

La presentación muestra que Antal Rohit Desai, director de PROCEPT BioRobotics (PRCT), ejerció opciones sobre acciones y adquirió 26.749 acciones el 14/08/2025 a un precio de ejercicio en efectivo de $1.33 por acción. Tras la operación posee beneficiariamente un total de 35.152 acciones, incluidas 14.363 acciones mantenidas indirectamente por The 2:22 DNA Trust. La opción ejercida estaba totalmente consolidada y era ejercitable, y el ejercicio se realizó en efectivo. El Formulario 4 fue firmado por un apoderado en nombre del Sr. Desai el 15/08/2025.

서류에 따르면 PROCEPT BioRobotics(PRCT)의 이사인 Antal Rohit Desai는 스톡옵션을 행사하여 2025년 8월 14일 주당 $1.33의 현금 행사가로 26,749주를 취득했습니다. 거래 후 그는 총 35,152주를 실질적으로 보유하게 되었으며, 그중 14,363주는 The 2:22 DNA Trust를 통해 간접 보유하고 있습니다. 행사된 옵션은 완전히 베스팅되어 행사 가능했으며, 행사는 현금으로 이루어졌습니다. Form 4는 2025년 8월 15일 Desai 씨를 대신한 대리인이 서명했습니다.

Le dépôt indique qu'Antal Rohit Desai, administrateur de PROCEPT BioRobotics (PRCT), a exercé des options sur actions et acquis 26 749 actions le 14/08/2025 au prix d'exercice en espèces de $1.33 par action. Après la transaction, il détient bénéficiairement au total 35 152 actions, dont 14 363 détenues indirectement par The 2:22 DNA Trust. L'option exercée était entièrement acquise et exerçable, et l'exercice a été effectué en espèces. Le formulaire 4 a été signé le 15/08/2025 par un mandataire ayant procuration au nom de M. Desai.

Die Einreichung zeigt, dass Antal Rohit Desai, ein Direktor von PROCEPT BioRobotics (PRCT), Aktienoptionen ausgeübt und am 14.08.2025 26.749 Aktien zu einem Barausübungspreis von $1.33 je Aktie erworben hat. Nach der Transaktion besitzt er wirtschaftlich insgesamt 35.152 Aktien, darunter 14.363 Aktien, die indirekt von The 2:22 DNA Trust gehalten werden. Die ausgeübte Option war vollständig unverfallbar und ausübbar, und die Ausübung erfolgte in bar. Das Formular 4 wurde am 15.08.2025 von einem Bevollmächtigten im Namen von Herrn Desai unterzeichnet.

Positive
  • Director increased ownership by exercising 26,749 options, raising beneficial holdings to 35,152 shares.
  • Options were fully vested and exercisable, and the exercise was completed as a cash transaction at $1.33 per share.
Negative
  • None.

Insights

TL;DR: Director exercised fully vested options to acquire 26,749 shares at $1.33, modestly increasing insider ownership.

The transaction is a routine insider option exercise rather than an open-market purchase or sale. A cash exercise of 26,749 options increases total reported beneficial ownership to 35,152 shares, with 14,363 shares held indirectly through a trust. For investors this is a limited, non-dilutive transfer from option to common stock that does not change company cash flow materially beyond the exercise proceeds.

TL;DR: This Form 4 documents a standard, fully vested option exercise by a director; disclosure appears complete and timely.

The filing identifies the reporter as a director and indicates the option was fully vested and exercised for cash. Reporting was done on a single-person Form 4 and signed by an attorney-in-fact. No additional derivative holdings remain for the reporter post-transaction. From a governance and disclosure standpoint, the Form 4 provides the required details: dates, quantities, price, and ownership form.

La comunicazione indica che Antal Rohit Desai, direttore di PROCEPT BioRobotics (PRCT), ha esercitato opzioni su azioni acquisendo 26.749 azioni il 14/08/2025 a un prezzo di esercizio in contanti di $1.33 per azione. Dopo la transazione detiene beneficiariamente in totale 35.152 azioni, comprese 14.363 azioni detenute indirettamente da The 2:22 DNA Trust. L'opzione esercitata era completamente maturata ed esercitabile, e l'esercizio è avvenuto in contanti. Il Modulo 4 è stato firmato da un mandatario per procura in nome del Sig. Desai il 15/08/2025.

La presentación muestra que Antal Rohit Desai, director de PROCEPT BioRobotics (PRCT), ejerció opciones sobre acciones y adquirió 26.749 acciones el 14/08/2025 a un precio de ejercicio en efectivo de $1.33 por acción. Tras la operación posee beneficiariamente un total de 35.152 acciones, incluidas 14.363 acciones mantenidas indirectamente por The 2:22 DNA Trust. La opción ejercida estaba totalmente consolidada y era ejercitable, y el ejercicio se realizó en efectivo. El Formulario 4 fue firmado por un apoderado en nombre del Sr. Desai el 15/08/2025.

서류에 따르면 PROCEPT BioRobotics(PRCT)의 이사인 Antal Rohit Desai는 스톡옵션을 행사하여 2025년 8월 14일 주당 $1.33의 현금 행사가로 26,749주를 취득했습니다. 거래 후 그는 총 35,152주를 실질적으로 보유하게 되었으며, 그중 14,363주는 The 2:22 DNA Trust를 통해 간접 보유하고 있습니다. 행사된 옵션은 완전히 베스팅되어 행사 가능했으며, 행사는 현금으로 이루어졌습니다. Form 4는 2025년 8월 15일 Desai 씨를 대신한 대리인이 서명했습니다.

Le dépôt indique qu'Antal Rohit Desai, administrateur de PROCEPT BioRobotics (PRCT), a exercé des options sur actions et acquis 26 749 actions le 14/08/2025 au prix d'exercice en espèces de $1.33 par action. Après la transaction, il détient bénéficiairement au total 35 152 actions, dont 14 363 détenues indirectement par The 2:22 DNA Trust. L'option exercée était entièrement acquise et exerçable, et l'exercice a été effectué en espèces. Le formulaire 4 a été signé le 15/08/2025 par un mandataire ayant procuration au nom de M. Desai.

Die Einreichung zeigt, dass Antal Rohit Desai, ein Direktor von PROCEPT BioRobotics (PRCT), Aktienoptionen ausgeübt und am 14.08.2025 26.749 Aktien zu einem Barausübungspreis von $1.33 je Aktie erworben hat. Nach der Transaktion besitzt er wirtschaftlich insgesamt 35.152 Aktien, darunter 14.363 Aktien, die indirekt von The 2:22 DNA Trust gehalten werden. Die ausgeübte Option war vollständig unverfallbar und ausübbar, und die Ausübung erfolgte in bar. Das Formular 4 wurde am 15.08.2025 von einem Bevollmächtigten im Namen von Herrn Desai unterzeichnet.

SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Desai Antal Rohit

(Last) (First) (Middle)
C/O PROCEPT BIOROBOTICS CORPORATION
150 BAYTECH DRIVE

(Street)
SAN JOSE CA 95134

(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
PROCEPT BioRobotics Corp [ PRCT ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
X Director 10% Owner
Officer (give title below) Other (specify below)
3. Date of Earliest Transaction (Month/Day/Year)
08/14/2025
4. If Amendment, Date of Original Filed (Month/Day/Year)
6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock 08/14/2025 M 26,749 A $1.33 35,152 D
Common Stock 14,363 I By The 2:22 DNA Trust
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Stock Option (Right to Buy) $1.33 08/14/2025 M(1) 26,749 (2) 09/17/2025 Common Stock 26,749 $0 0 D
Explanation of Responses:
1. Transaction is a cash exercise by the reporting person.
2. The option is fully vested and exercisable.
Remarks:
/s/ Jonathan Stone, Attorney-in Fact for Mr. Antal Rohit Desai 08/15/2025
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did PRCT director Antal Rohit Desai report on Form 4?

He reported a cash exercise of 26,749 stock options on 08/14/2025 at a price of $1.33 per share.

How many PRCT shares does Mr. Desai beneficially own after the transaction?

The Form 4 states he beneficially owns 35,152 shares following the reported transaction.

Does the filing disclose any indirect holdings for Mr. Desai?

Yes. The filing shows 14,363 shares are held indirectly through The 2:22 DNA Trust.

Was the option exercised by Mr. Desai vested at the time of exercise?

Yes. The filing explains the option was fully vested and exercisable at the time of the cash exercise.

Who signed the Form 4 filing for Mr. Desai?

The Form 4 was signed by Jonathan Stone, Attorney-in-Fact for Mr. Antal Rohit Desai on 08/15/2025.
Procept Biorobotics Corp

NASDAQ:PRCT

PRCT Rankings

PRCT Latest News

PRCT Latest SEC Filings

PRCT Stock Data

2.25B
53.29M
4.22%
93.86%
12.33%
Medical Devices
Surgical & Medical Instruments & Apparatus
Link
United States
SAN JOSE